Posted by Michael Wonder on 08 Dec 2017
Decision to fund methylnaltrexone in palliative care
8 December 2017 - PHARMAC is pleased to announce the approval of an agreement with Link Pharmaceuticals Limited for the listing of methylnaltrexone bromide (Relistor) injection in Section B (Community) and Part II of Section H (Hospital) of the Pharmaceutical Schedule from 1 January 2018.
Funding is subject to Special Authority criteria and DHB Hospital restrictions.
